Coating for medical device
Patent Information
- Application Number
- MYPI2025000694
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-29
- Filing Date
- 2023-07-31
- Publication Date
- 2024-01-29
AI Technical Summary
Existing coatings for medical devices have defects in drug release control and device matrix corrosion. In particular, the coating design of degradable medical devices is difficult to take into account the drug load, release rate and matrix corrosion control, resulting in uneven drug release or matrix corrosion. Premature corrosion.
A multi-layer coating structure is adopted, including a drug-loaded layer and a drug-controlled release layer. By optimizing the molecular weight, thickness and type of the polymer, combined with a metal isolation layer, the drug release and matrix corrosion are collaboratively controlled to ensure that the drug release rate and curve meet the needs. , while delaying or accelerating the degradation process of the device.
It achieves excellent drug release performance and effective control of matrix corrosion, avoiding the problem of sudden or insufficient drug release. It also ensures that the device does not undergo proliferation or inflammation after implantation and completes degradation in an appropriate time.
Smart Images

Figure PI2025000694_DRAWING_001 
Figure PI2025000694_DRAWING_002 
Figure PI2025000694_DRAWING_003
Abstract
Description
Coating for medical devices Technical Field
[0001] The present invention belongs to the technical field of medical devices, and specifically relates to a coating for medical devices, and more specifically to a degradable coating for medical devices. Background Art
[0002] Medical devices, especially implantable or interventional medical devices, are not only required to have basic therapeutic functions, but also to carry drugs on their surface to prevent rejection, proliferation, thrombosis, inflammation and other reactions at the implant site. Therefore, common medical devices currently have coatings added to their surfaces to carry drugs or control drug release. For example, after being implanted in a blood vessel, a vascular stent must not only expand the blood vessel and provide sufficient support for a certain period of time to ensure that the blood vessel remains unobstructed, but also prevent vascular proliferation, thrombosis at the implant site, and restenosis later in life. Therefore, vascular stents currently on the market usually have one or more layers of coating added to their surfaces to carry drugs and control drug release to prevent abnormal reactions after implantation in the human body, which would affect their basic therapeutic effects.
[0003] Devices have very strict requirements for drug loading and drug release on their surface coatings. Both the drug loading amount and the drug release rate must be controlled. If the drug loading is too high, the excess drug will cause significant toxic side effects in the human body, increasing the risk of drug toxicity in the body. If the drug loading is too low, the preventive and therapeutic effects will not be effective. Given a given total drug load in a medical device, if the drug release rate is too slow, insufficient drug will be available throughout the entire release phase, limiting the preventive and therapeutic effects. If the drug release rate is too fast, excessive local drug concentrations will result in toxic side effects. Furthermore, if the initial drug release is too rapid, sustained and effective drug release will not be achieved, leading to insufficient drug release later. In both cases, hyperplasia will occur at the implant site, ultimately causing vascular restenosis. Therefore, drug loading and controlled drug release on medical device surfaces are key challenges in designing drug coatings. For degradable medical devices, coatings not only need to load and control drug release but also play a role in controlling corrosion of the device substrate. Therefore, the design of coatings for degradable devices is an even greater problem and challenge.
[0004] Although a large number of research results related to drug coatings have been published, the vast majority of existing coatings for medical devices only consider drug release and do not consider the effect of the coating on the corrosion of the device substrate. Therefore, the design schemes of drug coatings that have been published so far are basically not suitable for use in biodegradable medical devices. On the one hand, some commonly used coatings are not perfect in terms of drug release and still have some defects. On the other hand, when the corrosion requirements of biodegradable medical devices are taken into account in the design of the coating, the type and molecular weight of the polymer in the coating will change greatly. Polymers of different types and molecular weights will have very different drug release control, and thus the design scheme of the entire coating will change greatly. For example, patent CN107496996B discloses a drug coating for a vascular stent. The coating comprises three layers, each containing a drug and a drug carrier. The outer coating layer controls the release of the inner coating layer, thereby reducing the burst release of the inner drug and lowering the possibility of acute toxic reactions. However, the outer layer of the drug coating also carries two drugs, and the molecular weight of the drug-loaded PLGA is relatively small, only about 2000. Furthermore, the mass fraction ratio of rapamycin, curcumin, and PLGA carrier loaded in the outer coating layer is 5:2:13. Therefore, the molecular weight of the polymer in the outer coating layer is small, the proportion of the polymer is low, and the proportion of the drug is large. The entire coating design does not have a good sustained-release effect on the drug in the outer layer, and the large amount of rapamycin loaded on the outer layer will also be released suddenly; both the middle layer and the outer layer are loaded with a large amount of rapamycin, which may cause the drug loading to significantly exceed the demand and produce additional toxic side effects to the human body; in addition, the substrate of the vascular stent is stainless steel, so the design of the drug coating in this patent application does not need to consider the degradation of the substrate. Therefore, the polymer used is a low-molecular-weight polymer and is not suitable for medical devices with degradable substrates.
[0005] Summary of the Invention
[0006] Based on this, the present application provides a coating for medical devices, especially a degradable coating for medical devices. Through the unique coating design, the coating ensures that the drug loading is within a suitable effective range, and the coating has very excellent performance in drug controlled release, and can also effectively control the corrosion of the substrate.
[0007] The technical solution of the present invention provides a coating for medical devices, which has very excellent performance in controlling drug release. Through the special design of the coating, it is more tolerant to the preparation process of the coating, the solvent used in the preparation process of the coating, and the crystal form and size of the drug in the final coating.
[0008] In the above technical solution of the present invention, the coating comprises a drug-loaded layer and a drug-controlled-release layer covering the drug-loaded layer, wherein both the drug-loaded layer and the drug-controlled-release layer contain polymers, and the molecular weight retention rate m and the weight average molecular weight Mw of the polymer in the drug-controlled-release layer are 控释 and the thickness of the polymer X 控释 The following relationship is satisfied:
[0009] in:
[0010] A1 is the fitting constant, which is 823;
[0011] A2 is the fitting constant, which is 79.9;
[0012] k is the fitting constant, which is 1.5;
[0013] b is the fitting constant, ranging from 0≤b≤2;
[0014] The Mw 控释 is the weight average molecular weight of the polymer in the drug controlled release layer, in kilodaltons, and the unit of X is μm.
[0015] It should be noted that b in the formula of the above technical solution can be any value in the range of 0-2. For example, in some embodiments of the present invention, b can be any value in the range of 0.2, 0.5, 0.55, 0.6, 0.65, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.85, 1.9, 1.95 or 2.0. In other embodiments of the present invention, b can be any value in the range of 0-2. The interval formed by any two values within the interval, such as 0.2-1.9, 0.5-1.5, 0.3-1.6, 0.3-1.2, 0.55-1.95, 0.6-1.95, 0.6-1.9, 0.6-1.85, 0.6-1.8, 0.6-1.7, 0.7-1.8, 0.75-1.6, 0.8-1.95, 0.8-1.9, 0.8-1.85, 0.8-1.8, 0.8-1.7 or 0.8-1.6, etc.
[0016] The present invention finds out the inherent correlation or regularity between the three variables of the coating thickness, polymer type and polymer molecular weight of the outer drug controlled release layer based on a large number of experimental records, and determines that the specific polymer and the molecular weight of the specific polymer in the outer drug controlled release layer must have a relatively better polymer thickness range corresponding to it. Within this optimal polymer thickness range, the performance of the coating in terms of drug release can be greatly improved. The present invention innovatively summarizes the relationship between the optimal thickness range of the drug controlled release layer and the type and molecular weight of the polymer through a large number of experimental results. That is, through the design of the above-mentioned special outer drug controlled release layer, the requirements for the process of the drug in the drug coating, the solvent used and the final drug crystal form are correspondingly relaxed, and the rate and curve of drug release basically meet the requirements of the corresponding medical device.
[0017] The medical device coating provided by the present invention is a relatively universal drug coating that is suitable for controlled release of drugs in both degradable and non-degradable medical devices. Preferably, the coating is suitable for degradable medical devices.
[0018] According to the above technical solution provided by the present invention, the weight average molecular weight Mw of the polymer in the drug controlled release layer is 控释 The molecular weight of the polymer in the drug controlled release layer of the technical solution of the present invention can be any value between 20 and 900 kDa. In some embodiments, the molecular weight of the polymer in the drug controlled release layer is 21 kDa; in other embodiments, the molecular weight of the polymer in the drug controlled release layer is 898 kDa; in other embodiments, the molecular weight of the polymer in the drug controlled release layer is 800 kDa; and in still other embodiments, the molecular weight of the polymer in the drug controlled release layer is 700 kDa.
[0019] According to the above technical solution provided by the present invention, the molecular weight retention rate m of the drug controlled release layer polymer is 50%-80%. The molecular weight retention rate m of the polymer in the present invention refers to the molecular weight retention rate of the polymer when the polymer coating is placed in a PBS solution (pH = 7.4) at a concentration of 37°C for 1 month, that is, the molecular weight retention rate m = Mw 控释1个月时 / Mw 控释 × 100%, where Mw 控释1个月时 Mw refers to the molecular weight of the polymer when the polymer coating is placed in PBS solution (pH = 7.4) at 37°C for 1 month. 控释 The molecular weight of the drug controlled release layer polymer is different for each polymer at the same time point under the same conditions. That is, in this application, each molecular weight retention rate represents a specific polymer, and different molecular weight retention rates represent different polymers.
[0020] The drug-carrying layer described in the present invention can be a single layer or multiple layers, and the drug loaded in the same drug-carrying layer can be one or more drugs. For example, in some embodiments, the drug-carrying layer is a single layer and loads a single drug; in other embodiments, the drug-carrying layer is a three-layer layer, each layer loading a different drug; in still other embodiments, the drug-carrying layer is a two-layer layer, one layer loading a single drug and the other layer loading two different drugs, i.e., the drug-carrying layer loads a total of three drugs; in still other embodiments, the drug-carrying layer is a two-layer layer, one layer loading two drugs and the other layer loading two different drugs, wherein the two drugs loaded in each layer can be completely different, partially identical, or completely identical.
[0021] According to the above technical solution provided by the present invention, the mass ratio of the drug to the polymer in the drug-carrying layer is 1:0.1-50; further, the mass ratio of the drug to the polymer in the drug-carrying layer is 1:(0.1-30) or 1:0.1-20; further, the mass ratio of the drug to the polymer in the drug-carrying layer is 1:(0.2-18), 1:(0.5-18), 1:(0.6-15), 1:(0.8-18), 1:(0.8-16), 1:(0.8- 15), 1:(0.5-12), 1:(0.5-8), 1:(0.5-6), 1:(0.2-16), 1:(0.2-12), 1:(0.1-12), 1:(0.2-10), 1:(0.1-10), 1:(0.2-8), 1:(0.1-8), 1:(0.2-5), 1:(0.2-4), 1:(0.2-3), 1:(0.1-5), 1:(0.1-4) or 1:(0.5-4).
[0022] According to the technical solution provided by the present invention, the particle size r of the drug particles in the drug-loading layer is ≤ 0.8 μm. The crystal form of the drug in the drug-loading layer can be crystalline, amorphous, or semi-crystalline. That is, in some embodiments of the present invention, the drug in the drug-loading layer is crystalline, in other embodiments, the drug in the drug-loading layer is amorphous, and in still other embodiments, the drug in the drug-loading layer is semi-crystalline. Due to the design of the special outer coating provided by the present invention, the present invention does not have too high requirements on the crystal form or grain size of the drug in the drug-carrying layer. That is, no matter whether the drug in the drug-carrying layer is in crystalline form, amorphous form, or semi-crystalline form, when the particle size of the drug is controlled below 0.8 μm, the drug release rate can meet the corresponding requirements. Therefore, the present application has a special design of the outer drug controlled-release layer and the drug-carrying layer, which greatly reduces the requirements for the process and solvent of the drug-carrying layer. As a result, the drug coating formed by different processes and solvents, as long as the particle size of the drug is not too large and the dispersion is relatively uniform, the drug release rate is within a relatively ideal range.
[0023] In some embodiments of the present invention, the particle size r of the drug particles in the drug-loaded layer is ≤0.8 μm; in other embodiments of the present invention, the particle size r of the drug particles in the drug-loaded layer is ≤0.6 μm; in other embodiments of the present invention, the particle size r of the drug particles in the drug-loaded layer is ≤0.45 μm.
[0024] It should be noted that the particle size described in the present invention refers to the average particle size. For example, "the particle size r of the drug particles in the drug-loading layer is 0.6 μm" means that the average particle size of the drug particles in the drug-loading layer is 0.6 μm, among which some drug particles may have a particle size greater than 0.6 μm, and some particles may have a particle size less than 0.6 μm.
[0025] It should also be noted that when the drug in the drug-loading layer is in a crystalline form, the particle size of the drug particles is the particle size of the crystal form; when the drug in the drug-loading layer is in an amorphous or semi-crystalline form, the particle size of the drug particles is the particle size of the drug clusters dispersed in the polymer.
[0026] According to the above technical solution provided by the present invention, the sum of the thickness of the drug-loaded layer and the drug-controlled-release layer is not less than 2.5 μm; further, the sum of the thickness of the drug-loaded layer and the drug-controlled-release layer is not less than 5 μm; further, the sum of the thickness of the drug-loaded layer and the drug-controlled-release layer is between (5 μm, 38 μm]. In some embodiments of the present invention, the sum of the thickness of the drug-loaded layer and the drug-controlled-release layer is 5.1 μm, 5.5 μm, 5.2 μm or 6 μm; in some embodiments of the present invention, the sum of the thickness of the drug-loaded layer and the drug-controlled-release layer is 7 μm, 7.5 μm or 8 μm.
[0027] According to the above technical solution provided by the present invention, the molecular weight of the polymer in the drug-carrying layer is 30-1000kDa; further, the molecular weight of the polymer in the inner layer and the middle layer is 40-1000kDa, 50-1000kDa, 60-1000kDa; further, the molecular weight of the polymer in the drug-carrying layer is 70-1000kDa, 80-1000kDa.
[0028] According to the above technical solution provided by the present invention, the inner side of the drug-carrying layer also includes a corrosion control layer, and the molecular weight of the polymer in the corrosion control layer is 50-1000kDa; further, the molecular weight of the polymers in the inner layer and the middle layer is 60-1000kDa, 70-1000kDa, and 80-1000kDa; further, the molecular weight of the polymer in the drug-carrying layer is 90-1000kDa and 100-1000kDa.
[0029] In the technical solution provided by the present invention, the molecular weight of the polymer in the drug-controlled release layer can fluctuate within a wide range, while the molecular weight requirements for the polymer in the drug-loading layer and the corrosion control layer are higher than those for the drug-controlled release layer. The polymer in the drug-loading layer serves as a carrier for the active drug. Its type, molecular weight, drug-loading coating thickness, and mass ratio with the drug all have a significant impact on the drug release rate. The higher the polymer molecular weight, the more pronounced the phase separation between the polymer and the drug, and the faster the drug release rate. The smaller the polymer mass to drug mass ratio, the weaker the polymer's ability to bind the drug, and the faster the drug release rate. The thinner the drug-loading coating, the shorter the drug diffusion release path, and the faster the drug release rate. In the corrosion control layer, the polymer molecular weight is relatively high. Too low a molecular weight can lead to rapid corrosion in the early stages, easily causing rapid corrosion of the degradable metal components in the device, failing to meet mechanical performance requirements, or causing premature polymer degradation, making it impossible to effectively regulate the rapid corrosion of the degradable metal components in the device later.
[0030] According to the above technical solution provided by the present invention, the total thickness of the corrosion control layer, the drug loading layer and the drug controlled-release layer is 3.5-45 μm; further, the total thickness of the corrosion control layer, the drug loading layer and the drug controlled-release layer is 5.5-40 μm; further, the total thickness of the corrosion control layer, the drug loading layer and the drug controlled-release layer is 5.8-36 μm.
[0031] According to the technical solution provided by the present invention, the thickness ratio of the corrosion control layer, the drug-carrying layer and the drug-controlled-release layer is 1:(0.5-15):(0.2-13).
[0032] According to the technical solution provided by the present invention, the thickness of the drug controlled-release layer is 0.2-8 μm; further, the thickness of the corrosion control layer is 0.5-7 μm; further, the thickness of the corrosion control layer is 0.8-6.6 μm.
[0033] According to the above technical solution provided by the present invention, the thickness of the corrosion control layer is 0.2-6 μm; further, the thickness of the corrosion control layer is 0.5-5 μm; further, the thickness of the corrosion control layer is 0.8-3 μm.
[0034] According to the technical solution provided by the present invention, the thickness of the drug-carrying layer is 1-8 μm; further, the thickness of the corrosion control layer is 1.5-7 μm; further, the thickness of the corrosion control layer is 1.5-6 μm.
[0035] According to the above technical solution provided by the present invention, in the three-layer structure of the coating, at least one layer further includes a corrosion promoter, a corrosion retardant or an antioxidant.
[0036] According to the technical solution provided by the present invention, the coating further includes a metal barrier layer located inside the corrosion control layer. The metal barrier layer is a coating containing a metal element that is more active than the medical device substrate. The metal coating can be densely and evenly distributed on the surface of the biodegradable device substrate through methods such as electroplating, spraying, or chemical plating.
[0037] According to the above technical solution provided by the present invention, the metal isolation layer can be used to delay the corrosion of the medical device substrate.
[0038] In some embodiments of the present invention, at least one metal in the metal barrier layer has an electronegativity less than that of the base metal of the degradable medical device, that is, at least one metal in the metal barrier layer is more active than the base metal of the degradable medical device. The metal barrier layer can be a pure metal or a metal alloy. When the metal barrier layer is a pure metal, the electronegativity of the metal is less than that of the base metal of the degradable medical device, that is, the metal is more active than the base metal of the degradable medical device. For example, when the base of the degradable medical device is iron-based, the metal barrier layer is pure zinc or pure magnesium. When the metal barrier layer is a metal alloy, the main metal element in the metal alloy, that is, the one or more elements with a higher content, is more active than the base metal of the degradable medical device, or has a lower electronegativity. For example, when the base of the degradable medical device is iron-based, the metal barrier layer is a zinc alloy or a magnesium alloy. In other embodiments of the present invention, the metal barrier layer can be a barrier layer containing a metal oxide. In some other embodiments of the present invention, the metal isolation layer may be any other metal-containing coating that can prevent corrosion of the medical device substrate.
[0039] According to the above technical solution provided by the present invention, when the metal in the absorbable metal matrix is pure iron or an iron-based alloy, the metal isolation layer includes pure magnesium, a magnesium-containing alloy, pure zinc or a zinc-containing alloy; when the metal in the absorbable metal matrix is pure zinc or a zinc-containing alloy, the metal isolation layer includes pure magnesium or a magnesium-containing alloy.
[0040] Since the metal in the metal isolation layer is relatively more active than the metal constituting the device substrate, electrochemical protection can be formed in the in vivo microenvironment. The relatively active metal in the isolation layer corrodes first, while the device substrate that plays a supporting role is protected to delay its corrosion. For example, when the device substrate is iron or iron alloy, covering the surface of the device with a metal coating composed of zinc or zinc alloy will form a primary battery in the in vivo microenvironment. The metal coating composed of zinc or zinc alloy acts as the negative electrode, loses electrons and becomes zinc ions, and is corroded first, while the iron or iron alloy device substrate acts as the positive electrode and is temporarily protected from corrosion.
[0041] The four schemes of the present invention, namely, a drug-controlled release layer, a drug-loading layer, or a drug-controlled release layer, a drug-loading layer and a corrosion control layer, or a drug-controlled release layer, a drug-loading layer and a metal barrier layer, or a drug-controlled release layer, a drug-loading layer, a corrosion control layer and a metal barrier layer, can all achieve both controlled drug release and controlled substrate corrosion. The parameters of the various layers of the coating in each scheme cooperate and match with each other to achieve the purpose of the present invention. For example, in some embodiments of the present invention, the coating for medical devices comprises, from the outside to the inside, a drug-controlled release layer and a drug-loading layer, or a drug-controlled release layer, a drug-loading layer and a corrosion control layer. By adjusting the polymer type, polymer molecular weight and coating thickness of each layer of the coating, as well as the drug loading amount within the corresponding range, the final coating can have both excellent drug release performance and excellent corrosion control performance, so that after the device is implanted in the corresponding part, neither proliferation nor inflammation occurs, and at the same time, no corrosion or slow corrosion occurs in the first 1-6 months, and rapid corrosion occurs after 6 months.
[0042] According to the technical solution provided by the present invention, the thickness of the metal barrier layer is ≥ 0.6 μm. Furthermore, the thickness of the metal barrier layer is between 0.6 and 3.8 μm. When the metal barrier layer is thick enough, it can effectively prevent premature corrosion of the base metal of the degradable medical device, thereby ensuring that the base metal can meet the requirements of no corrosion within the first 1-6 months. The thickness of the metal barrier layer should not be too thick, otherwise it will not be completely corroded within 2 years, ultimately resulting in the degradable medical device not being able to corrode rapidly after 6 months and not being completely corroded within 2 years.
[0043] According to the above technical solution provided by the present invention, the polymer in the coating is at least one of a degradable polyester or a degradable polyanhydride; further, the polymer in the present invention is selected from at least one of polyracemic lactic acid, poly-L-lactic acid, poly-D-lactic acid, polyhydroxyethyl ester, polyurethane, polyamino acid, poly(lactic diglycolic acid) acid, poly-D,L-lactide, polypropylene glycol, polyglycolic acid, polylactic glycolic acid, polysalicylic anhydride, polytrimethylene carbonate, polycaprolactone, polycaprolactone, polyhydroxyalkanoate, polyacrylate, polysuccinate, poly(β-hydroxybutyrate) and polyethylene adipate, poly 1,3-bis(p-carboxyphenoxy)propane-sebacic acid, polyerucic acid dimer-sebacic acid and polyfumaric acid-sebacic acid. In some embodiments of the present invention, the polymer in the coating can be a specific one of the above-mentioned polymers, such as the polymers in the drug controlled release layer, the corrosion control layer and the corrosion control layer in the coating are all polyracemic lactic acid; in other embodiments of the present invention, the polymer in the coating can be a mixture of two or more of the above-mentioned polymers, such as a mixture of two or more of poly (L-lactic acid), poly (D-lactic acid), polyurethane, polysalicylic acid anhydride ester, polytrimethylene carbonate or polycaprolactone; the mixture of two or more can be a layer containing two polymers at the same time, or each single layer can contain only one different polymer. For example, in some embodiments of the present invention, the polymer in the outer drug-controlled release layer of the coating is poly(L-lactic acid), the polymer in the drug-carrying layer is poly(racemic) lactic acid, and the polymer in the corrosion control layer is polyurethane; in other embodiments of the present invention, the drug-controlled release layer, the corrosion control layer and the polymer in the corrosion control layer in the coating are all polyurethane and polysalicylic acid anhydride ester, or a mixture of poly(racemic) lactic acid, poly(L-lactic acid) and poly(D-lactic acid); in some other embodiments, the polymers in the drug-controlled release layer and the corrosion control layer in the coating are poly(racemic) lactic acid, and the polymer in the corrosion control layer is a mixture of polyhydroxyalkanoate and polyacrylate.
[0044] According to the above technical solution provided by the present invention, the drug loaded in the coating is at least one of a drug that inhibits angiogenesis, an anti-inflammatory drug, an antithrombotic drug, and a sensitizing drug; the antithrombotic drug includes an antiplatelet drug and an anticoagulant drug. In some embodiments of the present invention, the drug loaded in the coating is only a drug that inhibits angiogenesis; in other embodiments, the drug loaded in the coating is a combination of any two or more of a drug that inhibits angiogenesis, an anti-inflammatory drug, an antithrombotic drug, and a sensitizing drug. More specifically, the drug that inhibits angiogenesis described in the present invention is selected from at least one of paclitaxel, rapamycin, and its derivatives; the antiplatelet drug includes cilostazol; the antithrombotic drug includes heparin; the anti-inflammatory drug is dexamethasone; and the anti-sensitizing drug is selected from at least one of calcium gluconate, chlorpheniramine, and cortisone.
[0045] According to the technical solution provided by the present invention, the drug loaded in the drug-carrying layer is at least one of paclitaxel, rapamycin, cilostazol, heparin, tacrolimus, everolimus, dexamethasone, calcium gluconate, chlorpheniramine or cortisone.
[0046] According to the above technical solution provided by the present invention, the medical device is a degradable metal medical device or a degradable non-metallic medical device, and the metal is a pure metal or a metal alloy. Furthermore, the degradable medical device is a medical device that at least partially includes an iron-based, zinc-based, polymer-based, and magnesium-based material. In some embodiments of the present invention, the matrix of the degradable medical device is composed of a metal or metal alloy, such as the entire degradable medical device is an iron-based medical device; in other embodiments of the present invention, the matrix of the degradable medical device is composed of two or more materials, such as partly iron-based and partly zinc-based, or partly metal-based and partly non-metal-based.
[0047] According to the above technical solution provided by the present invention, the medical device includes any one of a vascular stent, a heart valve, a non-vascular intraluminal stent, an occluder, an orthopedic implant, a dental implant, a respiratory implant, a gynecological implant, a men's implant, a suture or a bolt.
[0048] According to the above technical solution provided by the present invention, the stent described in the present invention is an intravascular stent or a stent for a heart valve; further, the stent described in the present invention is a balloon-expandable stent or a self-expanding stent; further, the stent described in the present invention includes a coronary stent, a below-knee stent, a superficial femoral stent, an intracranial stent, a carotid artery stent, a pulmonary artery stent or a renal artery stent.
[0049] According to the above technical solution provided by the present invention, the substrate of the biodegradable medical device is pure iron or an iron-based alloy with a carbon content of no more than 2.11 wt%.
[0050] It should be noted that the metal in the aforementioned iron-based, zinc-based or magnesium-based materials refers to the main component of the matrix. For example, the iron-based material includes pure iron or iron alloy, which means that the main component of the matrix is iron.
[0051] The present invention controls the release of drugs from the drug-loaded layer through the relationship or inherent logic among the polymer type, polymer molecular weight and polymer thickness of the drug-controlled release layer. The drug-controlled release layer provided in the present invention can effectively prevent the drug in the drug-loaded layer from being rapidly released under the flushing of blood when the stent is just implanted into the human body, resulting in excessive early drug release and insufficient later drug release, which cannot effectively and sustainably release drugs, thereby avoiding restenosis of the blood vessels. That is, the drug-controlled release layer in the present invention has a certain protective effect on the drug-loaded layer and can also regulate the release rate of the drugs loaded in the drug-loaded layer. The present invention adds a special drug-controlled release layer outside the drug-loaded layer. The drug in the drug-loaded layer will gradually increase the contact area between the drug-loaded layer and the blood only after the polymer of the drug-controlled release layer is degraded to a certain extent. Therefore, the problem of early drug burst release after stent implantation can be effectively controlled.
[0052] The drug controlled-release layer and the drug-loading layer in the present invention work together to control the release of the drug. On the one hand, the release rate of the drug in each stage is effectively controlled to ensure that the amount of drug released in each stage just meets the demand; on the other hand, the drug-loading layer is loaded with an appropriate amount of drug as much as possible to prevent excessive drug loading from having certain toxic side effects on the human body. That is, while controlling the drug release to ensure that the drug amount just meets the demand, the total drug loading is reduced as much as possible.
[0053] The drug-controlled release layer, drug-carrying layer, and corrosion-promoting layer of the present invention all contain polymers. The thickness and molecular weight of the polymers in the three coatings work synergistically to control the corrosion of the device substrate, or the device substrate and metal barrier layer. In some embodiments provided herein, when the molecular weight of the polymer in the drug-controlled release layer is relatively low, in order to control the overall corrosion rate of the final device substrate, the type and molecular weight of the polymers in the drug-carrying layer and the corrosion-control layer can be adjusted to meet the requirements. For example, the molecular weight of the polymers in the drug-carrying layer and the corrosion-control layer can be increased, while polymers with relatively slow degradation rates can be selected.
[0054] The metal isolation layer introduced in the technical solution of the present invention can control the corrosion rate of the device substrate together with the above-mentioned polymer-containing coating, ensuring that the device is not corroded in the early stage of implantation (1-6 months), but when the vascular repair is completed, the device substrate is allowed to degrade rapidly. In the in vivo environment, the corrosion control layer and the metal isolation layer are degraded at the same time. The degradable polyester constituting the corrosion control layer will produce acidic substances when degrading. When the degradation accumulates to a certain extent, a local acidic environment can be formed, thereby aggravating the corrosion and degradation of the metal isolation layer and the medical device substrate. This process can be controlled by the thickness and molecular weight of the degradable polyester of the corrosion control layer. The lower the molecular weight, the thicker the thickness of the degradable polyester, and the faster the corrosion and degradation of the metal isolation layer and the stent.
[0055] The polymers in the corrosion control layer, drug-carrying layer and drug-controlled release layer of the present invention work together to control the corrosion of the device substrate or the device substrate and the metal isolation layer. At the same time, the corrosion control layer can also isolate the metal ions generated by the device substrate and the metal isolation layer during the corrosion process from the human body environment, preventing the metal ions from combining with the active drug and then transferring unimpeded into the human blood vessels, thereby causing hemolysis, or preventing excessive metal ions from directly contacting the human body and causing local poisoning or thrombosis.
[0056] It should be understood that the terms used herein are for the purpose of describing specific example embodiments only and are not intended to be limiting. Unless the context clearly indicates otherwise, the singular forms "one", "an" and "said" as used herein may also be meant to include plural forms. The terms "comprise", "include", "contain" and "have" are inclusive and therefore specify the presence of stated features, steps, operations, elements and / or parts, but do not exclude the presence or addition of one or more other features, steps, operations, elements, parts, and / or combinations thereof. The method steps, processes, and operations described herein are not to be construed as necessarily requiring them to be performed in the specific order described or illustrated, unless the order of execution is clearly indicated. It should also be understood that additional or alternative steps may be used. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Various other advantages and benefits will become apparent to those skilled in the art upon reading the detailed description of the preferred embodiment below. The accompanying drawings are for illustration purposes only and are not to be considered as limiting the present invention. The same reference numerals are used throughout the accompanying drawings to denote the same components.
[0058] FIG1 is a Raman spectrum of the thickness test of each layer in the stent coating in Example 1, wherein: 1-metal isolation layer, 2-corrosion control layer, 3-drug-loading layer, 4-drug controlled release layer, 5-embedded sample material epoxy polyester;
[0059] Figure 2 is an SEM image of the drug particle size test in the drug-loaded layer of Example 1 and Example 6, wherein Figure 2-1 is a cross-section of the ethyl acetate solvent spray coating at time zero in Example 6; Figure 2-2 is a cross-section of the ethyl acetate solvent spray coating in Example 6 after drug extraction; Figure 2-3 is a cross-section of the chloroform solvent spray coating in Example 1 after drug extraction;
[0060] FIG3 is an XRD diagram of the drug crystallinity test in the drug-carrying layer of Example 1 and Example 6;
[0061] FIG4 is a graph showing the drug release rates of the absorbable stent coatings in Examples 1-7 and Comparative Examples 1-5;
[0062] FIG5 is a graph showing the percentage of mass loss of the absorbable stents in Examples 1-7 and Comparative Examples 1-5 in animals;
[0063] FIG6 is a test diagram of the radial support strength of the absorbable stents in Examples 1-7 and Comparative Examples 1-5 in animals. DETAILED DESCRIPTION
[0064] The following description is merely a preferred embodiment of the present invention, and the present invention is not limited to the following preferred embodiments. For example, the examples are described using stents as examples, but this does not mean that the technical solutions of the present invention are only applicable to stents. It should be noted that for those skilled in the art, various variations and improvements based on this inventive concept are within the scope of protection of the present invention. Reagents or instruments used without manufacturer indication are all commercially available conventional products.
[0065] Test Method
[0066] 1. Determination of weight average molecular weight of polymer
[0067] The molecular weight test was performed using a Wyatt GPC-multi-angle laser light scattering system. The system consisted of an Agilent liquid phase pump and injector, an Agilent PL MIXED-C GPC column (7.5 x 300 mm, 5 μm), a Wyatt multi-angle laser light scattering instrument, and a differential detector. The test conditions were as follows:
[0068] Mobile phase: tetrahydrofuran; pump flow rate: 1 mL / min; injection volume: 100 μL; laser wavelength: 663.9 nm; test temperature: 35°C.
[0069] 2. Determination of the thickness of the metal isolation layer
[0070] To measure the thickness of a metal barrier layer using an X-ray fluorescence coating thickness gauge: First, calibrate the device using a standard block of the corresponding element. After calibration, secure the bracket sample to be tested for the metal barrier layer thickness to the sample stage and place it in the X-ray fluorescence coating thickness gauge. Set the coating and base metal types, the measurement time to 10-15 seconds, and the thickness in μm. Click OK to test the metal barrier layer thickness.
[0071] 3. Determination of total thickness of polymer coating
[0072] Measurement using a scanning electron microscope: First, secure the stent sample whose coating thickness needs to be tested to the sample stage. Then place the sample stage in the JFC-1600 gold spraying equipment and spray it with platinum. After spraying once, rotate it 180° and spray it again to ensure that all positions are sprayed. Place the sample with the platinum sprayed on the surface into a mixture of Buehler room temperature resin and hardener prepared in a ratio of 5:1. Let it stand for more than 8 hours before removing it from the sample shell. Divide the sealed sample into 3 equal sections. Polish each section using a semi-automatic grinder and polisher according to the sample polishing procedure. Polish the sample section to be measured until there are no wear marks. Secure the polished sample to the stage of the scanning electron microscope, and place the entire stage in the JFC-1600 gold spraying equipment and spray it with gold for 20 seconds. Place the gold-sprayed sample in a JSM-6510 scanning electron microscope for thickness measurement.
[0073] 4. Test method for thickness of each layer of multi-layer drug coating
[0074] First, fix the stent sample to be tested for multi-layer drug coating characterization on the sample stage. Then place the sample stage in the JFC-1600 gold spraying equipment and spray it with platinum. After spraying once, rotate it 180° and spray it again to ensure that all positions are sprayed. Place the sample with the gold sprayed surface in a mixed reagent of Buehler room temperature resin curing agent prepared in a ratio of 5:1. Let it stand for more than 8 hours before removing it from the sample shell. Divide the sealed sample into 3 sections evenly. Polish each section with a semi-automatic grinder according to the sample polishing procedure. Polish the sample section to be measured until there are no wear marks. Fix the polished sample to the stage of the scanning electron microscope, and place the entire stage in the JFC-1600 gold spraying equipment to spray gold for 20 seconds.
[0075] The cross section of the coating portion of the multilayer coated medical device was scanned using a Thermo DXR2 micro-Raman spectrometer with laser energy parameters of 6.0 mW, exposure time of 20 Hz, exposure times of 50, and magnification of 500 times.
[0076] Through YZ cross-sectional scanning, the component distribution diagram of the cross section can be obtained. The characteristic peaks of drugs and polylactic acid can be used to qualitatively analyze the drug and polylactic acid content in different areas and test the thickness of each coating.
[0077] 5. Particle size test method for drug particles in coatings
[0078] After the coatings made with different solvents were vacuum-dried at room temperature for 24 hours, they were placed in a 5 mL isopropanol solution and shaken at 100 rpm at 37°C for 30 minutes. After the drug was fully extracted by isopropanol, the coating was taken out and vacuum-dried for 24 hours, and then placed in liquid nitrogen for brittle coating treatment. The sample after brittle coating treatment was fixed on the stage of the scanning electron microscope, and the entire stage was placed in the JFC-1600 gold spraying equipment for gold spraying for 20 seconds. The gold-sprayed sample was placed in the JSM-6510 scanning electron microscope to measure the pore size left after the drug extraction, and the particle size of the drug particles could be measured.
[0079] 6. Test method for drug crystallinity in coatings
[0080] The coating solutions prepared with different solvents (ethyl acetate, chloroform) were uniformly sprayed onto a stainless steel plate using a spraying device and vacuum dried at room temperature for 24 hours to obtain drug / polymer coating films prepared with different solvents.
[0081] XRD tests were performed on drug / polymer films prepared with different solvents (Bruker D2PHASER). The samples were scanned in θ-2θ linkage mode with a scanning angle range of 3-40°, a scanning step of 0.02°, and a scanning speed of 4° / min.
[0082] 7. Test method for drug release rate of multi-layer coated medical devices in animals
[0083] The multi-layer coated medical device was implanted into the blood vessels of healthy rabbits. At predetermined observation time points, such as 7 hours, 1 day, 3 days, 7 days, 14 days, 28 days, 60 days, 90 days, and 180 days, the rabbits were respectively killed and the multi-layer coated medical device was taken out. After removing the tissue on the medical device as much as possible, it was placed in a brown glass bottle and an appropriate amount of acetonitrile was added to the volume. The volume can be determined according to the specific specifications to ensure that the stent can be completely immersed in the solution. Ultrasonic treatment was performed for 15 minutes, filtered with a 0.22μm nylon organic filter membrane, and then loaded into a chromatograph injection bottle, and the residual drug amount of the stent was tested using a liquid chromatograph. The drug release amount of the stent is the initial drug amount on the stent minus the residual drug amount (test drug amount) on the stent after immersion, and the drug release percentage is the ratio of the drug release amount to the initial drug amount.
[0084] Chromatographic conditions: acetonitrile:water = 65:35 solution as mobile phase, flow rate 1.0 ml / min, detection wavelength 278 nm, column temperature 50°C, injection volume 10.0 μl.
[0085] 8. In vivo mass loss test of absorbable stents in animals
[0086] The multi-layer coated medical device was implanted into the blood vessels of healthy rabbits. At predetermined observation time points, such as 7 hours, 1 day, 3 days, 7 days, 14 days, 28 days, 60 days, 90 days, and 180 days, the rabbits were sacrificed and the multi-layer coated medical device was removed. After removing as much tissue as possible from the medical device, the remaining drug content in the stent was determined using a liquid chromatograph. The stent, after the drug content was determined, was washed with ethyl acetate to completely dissolve the polymer coating.
[0087] The cleaned stent was inspected by micro-CT to qualitatively analyze the corrosion of the iron-based substrate. Afterwards, the stent was placed in a tartaric acid solution and ultrasonically cleaned to remove the surface corrosion product layer. After drying, the stent was weighed to m 腐蚀后 .
[0088] The mass loss rate of the device m% is the mass of the device before corrosion m 腐蚀前 The mass m of the device after corrosion and treatment 腐蚀后 The difference between the mass m of the instrument before corrosion 腐蚀前 The ratio is multiplied by 100%, that is:
[0089] 9. Stent radial support strength test
[0090] The stent is expanded with a suitable balloon (or distal component) to a nominal pressure so that the outer diameter of the stent sample reaches a predetermined size.
[0091] Stent length was measured using a 3D microscope, and a support force curve test was performed with 50% compression as the endpoint. Radial support strength is expressed as the force per unit length when the stent's nominal diameter is compressed by 10%, which is the numerical value of the stent's radial compressive resistance (unit: kPa).
[0092] Example 1
[0093] In this embodiment, an iron-based bracket with a specification of 3.0 mm×8 mm is selected, and a zinc layer with an average thickness of 0.6 μm is plated on the surface of the substrate by electroplating as a metal isolation layer. On the outside of the metal isolation layer, a corrosion control layer with an average thickness of 3 μm was evenly sprayed using a stent spraying device. The coating layer was made of polyracemic lactic acid with a molecular weight of 600 kDa and chloroform was used as the solvent. After the corrosion control layer was dried, a drug-loaded layer with an average thickness of 5 μm was evenly sprayed using a stent spraying device. The coating layer was made of polyracemic lactic acid with a molecular weight of 400 kDa and chloroform was used as the solvent. Sirolimus was selected as the loaded drug. The mass ratio of sirolimus to polyracemic lactic acid in the drug-loaded layer was 1:0.5. The average particle size of the drug particles was 0.25 μm, and the drug particles were amorphous (see Figure 3). After the drug-loaded layer was dried, a drug release control layer with an average thickness of 3 μm was evenly sprayed using a stent spraying device. The coating layer was made of polyracemic lactic acid with a one-month molecular weight retention rate of 74%, a molecular weight of 200 kDa, and ethyl acetate was used as the solvent.
[0094] The in vivo drug release rate of the stent in this example is shown in Figure 4, the stent mass loss is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. No thrombosis was observed in the vessel where the stent was implanted, and the lumen was unobstructed with no restenosis. The coating ensures that the stent maintains sufficient support within six months and completely degrades within two years.
[0095] Example 2
[0096] In this example, an iron-based stent measuring 3.0 mm x 8 mm was used. A zinc layer with an average thickness of 2 μm was electroplated onto the substrate surface as a metal barrier layer. A drug-loading layer with an average thickness of 10 μm was evenly sprayed onto the metal barrier layer using stent spraying equipment. The coating layer consisted of poly(lactic acid) with a molecular weight of 400 kDa, using chloroform as the solvent. Sirolimus was the drug-loading agent, with a mass ratio of sirolimus to poly(lactic acid) of 1:8. The drug particles had an average particle size of 0.35 μm and were amorphous. After the drug-loading layer dried, a drug-release control layer with an average thickness of 1.8 μm was evenly sprayed onto the stent spraying equipment using poly(lactic acid) with a molecular weight of 400 kDa and a one-month molecular weight retention rate of 79%, using chloroform as the solvent.
[0097] The in vivo drug release rate of the stent in this example is shown in Figure 4, the stent mass loss is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. No thrombosis was observed in the vessel where the stent was implanted, and the lumen was unobstructed with no restenosis. The coating ensures that the stent maintains sufficient support within six months and completely degrades within two years.
[0098] Example 3
[0099] In this embodiment, an iron-based bracket with a specification of 3.0 mm×8 mm is selected, and a zinc layer with an average thickness of 3 μm is plated on the surface of the substrate by electroplating as a metal isolation layer. Outside the metal isolation layer, a corrosion control layer with an average thickness of 6 μm was evenly sprayed using a stent spraying device. The coating layer used PLGA (50:50), a molecular weight of 50 kDa, and a solvent of chloroform. After the corrosion control layer was dried, a drug-loaded layer with an average thickness of 5 μm was evenly sprayed using a stent spraying device. The coating layer used PLGA (50:50), a molecular weight of 50 kDa, and a solvent of chloroform. Sirolimus was selected as the loaded drug. The mass ratio of sirolimus to PLGA in the drug-loaded layer was 1:1.25. The average particle size of the drug particles was 0.45 μm, and the drug particles were amorphous. After the drug-loaded layer was dried, a drug release control layer with an average thickness of 6 μm was evenly sprayed using a stent spraying device. The coating layer used PLGA (50:50), a molecular weight of 50 kDa, a one-month molecular weight retention rate of 61%, and a solvent of chloroform.
[0100] The in vivo drug release rate of the stent in this example is shown in Figure 4, the stent mass loss is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. No thrombosis was observed in the vessel where the stent was implanted, and the lumen was unobstructed without stenosis. The coating ensures that the stent maintains sufficient support within six months and completely degrades within two years.
[0101] Example 4
[0102] In this embodiment, an iron-based bracket with a specification of 3.0 mm×8 mm is selected, and a zinc layer with an average thickness of 3.8 μm is plated on the surface of the substrate by electroplating as a metal isolation layer. Outside the metal isolation layer, a bracket spraying device is used to evenly spray a corrosion control layer with an average thickness of 5 μm. The coating layer is made of polyracemic lactic acid with a molecular weight of 400 kDa and ethyl acetate is used as the solvent. After the corrosion control layer is dried, a bracket spraying device is used to evenly spray a drug-loaded layer with an average thickness of 4 μm. The coating layer is made of polyracemic lactic acid with a molecular weight of 200 kDa and ethyl acetate is used as the solvent. The drug loaded is sirolimus. The mass ratio of sirolimus to polyracemic lactic acid in the drug-loaded layer is 1:2. The average particle size of the drug particles is 0.2 μm, and the drug particles are semi-crystalline. After the drug-loaded layer is dried, a bracket spraying device is used to evenly spray a drug release control layer with an average thickness of 0.8 μm. The coating layer is made of polyracemic lactic acid with a one-month molecular weight retention rate of 81%, a molecular weight of 800 kDa, and chloroform is used as the solvent.
[0103] The in vivo drug release rate of the stent in this example is shown in Figure 4, the stent mass loss is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. No thrombosis was observed in the vessel where the stent was implanted, and the lumen was unobstructed with no restenosis. The coating ensures that the stent maintains sufficient support within six months and completely degrades within two years.
[0104] Example 5
[0105] In this example, an iron-based stent measuring 3.0 mm x 8 mm was electroplated with a zinc layer with an average thickness of 1 μm as a metal barrier layer. A corrosion control layer with an average thickness of 3.5 μm was evenly sprayed onto the metal barrier layer using stent spraying equipment. The coating was made of poly(lactic acid) with a molecular weight of 200 kDa and ethyl acetate as the solvent. After the corrosion control layer dried, a drug-loading layer with an average thickness of 5 μm was evenly sprayed onto the stent spraying equipment using poly(lactic acid) with a molecular weight of 100 kDa and ethyl acetate as the solvent. Sirolimus was the drug-loading layer. The mass ratio of sirolimus to poly(lactic acid) in the drug-loading layer was 1:1.5, and the drug particles had an average particle size of 0.7 μm and were semi-crystalline. After the drug-loading layer dried, a drug-release control layer with an average thickness of 5.8 μm was evenly sprayed onto the stent spraying equipment using poly(lactic acid) with a molecular weight of 50 kDa and a one-month molecular weight retention rate of 63% and ethyl acetate as the solvent.
[0106] The in vivo drug release rate of the stent in this example is shown in Figure 4, the stent mass loss is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. No thrombosis was observed in the vessel where the stent was implanted, and the lumen was unobstructed with no restenosis. The coating ensures that the stent maintains sufficient support within six months and completely degrades within two years.
[0107] Example 6
[0108] In this embodiment, an iron-based bracket with a specification of 3.0 mm×8 mm is selected, and a zinc layer with an average thickness of 2.5 μm is plated on the surface of the substrate by electroplating as a metal isolation layer. On the outside of the metal isolation layer, a corrosion control layer with an average thickness of 2.5 μm was evenly sprayed using a stent spraying device. The coating layer was made of polyracemic lactic acid with a molecular weight of 300 kDa and the solvent was ethyl acetate. After the corrosion control layer was dried, a drug-loaded layer with an average thickness of 8 μm was evenly sprayed using a stent spraying device. The coating layer was made of polyracemic lactic acid with a molecular weight of 300 kDa and the solvent was ethyl acetate. The drug loaded was sirolimus. The mass ratio of sirolimus to polyracemic lactic acid in the drug-loaded layer was 1:6. The average particle size of the drug particles was 0.35 μm, and the drug particles were semi-crystalline (see Figure 3). After the drug-loaded layer was dried, a drug release control layer with an average thickness of 2.6 μm was evenly sprayed using a stent spraying device. The molecular weight was 600 kDa, the one-month molecular weight retention rate was 80%, and the solvent was chloroform.
[0109] The drug release rate of the stent in this embodiment is shown in Figure 4, the mass loss of the stent is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. No thrombosis was observed in the blood vessel where the stent was located during the entire implantation stage, and the lumen was unobstructed without restenosis.
[0110] Example 7
[0111] In this example, an iron-based stent with a size of 3.0 mm x 8 mm was used. A zinc layer with an average thickness of 1.5 μm was electroplated on the substrate surface as a metal barrier layer. A corrosion control layer with an average thickness of 2 μm was evenly sprayed onto the metal barrier layer using stent spraying equipment. The coating was made of poly(lactic acid) with a molecular weight of 200 kDa and acetone as the solvent. After the corrosion control layer dried, a drug-loaded layer with an average thickness of 3 μm was evenly sprayed onto the stent spraying equipment using poly(lactic acid) with a molecular weight of 600 kDa and acetone as the solvent. Sirolimus was the drug-loaded drug. The mass ratio of sirolimus to poly(lactic acid) in the drug-loaded layer was 1:1.5, and the average particle size of the drug particles was 0.6 μm. After the drug-loaded layer dried, a drug-release control layer with an average thickness of 6.6 μm was evenly sprayed onto the stent spraying equipment using acetone as the solvent. The drug-release control layer had a molecular weight of 100 kDa and a one-month molecular weight retention rate of 65%.
[0112] The in vivo drug release rate of the stent in this example is shown in Figure 4, the stent mass loss is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. No thrombosis was observed in the vessel where the stent was implanted, and the lumen was unobstructed with no restenosis. The coating ensures that the stent maintains sufficient support within six months and completely degrades within two years.
[0113] Comparative Example 1
[0114] This example uses an iron-based stent with a size of 3.0 mm x 8 mm. A zinc layer with an average thickness of 1 μm is electroplated on the substrate surface as a metal barrier layer. A corrosion control layer with an average thickness of 3 μm is evenly sprayed on the metal barrier layer using stent spraying equipment. The coating layer is made of poly (racemic lactic acid) with a molecular weight of 400 kDa and a solvent of ethyl acetate. After the corrosion control layer has dried, a drug-carrying layer with an average thickness of 5 μm is evenly sprayed using the stent spraying equipment. The coating layer is made of poly (racemic lactic acid) with a molecular weight of 200 kDa and a solvent of ethyl acetate. The drug carrier is sirolimus. The mass ratio of sirolimus to poly (racemic lactic acid) in the drug-carrying layer is 1:2, and the drug particles have an average particle size of 0.3 μm and are semi-crystalline.
[0115] The in vivo drug release rate of the stent in this comparative example is shown in Figure 4. As can be seen, the stent in this comparative example experienced a burst of drug release early in the implant period, releasing the majority of the drug early in the implant period. This resulted in insufficient drug release in the middle and later stages. At 90 days, the vessel in which the stent was located showed signs of severe hyperplasia. Stent mass loss is shown in Figure 5, and radial support strength is shown in Figure 6. The stent exhibited normal in vivo corrosion rates and continued to provide effective support at six months.
[0116] Comparative Example 2
[0117] This embodiment uses an iron-based stent with a size of 3.0 mm x 8 mm. A zinc layer with an average thickness of 1.5 μm is electroplated on the substrate surface as a metal barrier layer. A corrosion control layer with an average thickness of 5 μm is evenly sprayed on the metal barrier layer using stent spraying equipment. The coating layer is made of poly(lactic acid) with a molecular weight of 200 kDa and a solvent of chloroform. After the corrosion control layer has dried, a drug-carrying layer with an average thickness of 5 μm is evenly sprayed using the stent spraying equipment. The coating layer is made of poly(lactic acid) with a molecular weight of 200 kDa and a solvent of chloroform. The drug-carrying layer contains sirolimus, with a mass ratio of sirolimus to poly(lactic acid) of 1:1.25. The coating layer is made of poly(lactic acid) with a molecular weight of 400 kDa and a solvent of chloroform. The drug-carrying layer contains sirolimus, with an average particle size of 0.35 μm and amorphous particles.
[0118] The drug release rate of the stent in this comparative example in vivo is shown in Figure 4. As can be seen from Figure 4, the stent in this comparative example releases drugs in an early stage, releasing most of the drugs in the early stage of stent implantation, resulting in insufficient drug release in the middle and late stages. At the 90-day time point, relatively serious signs of proliferation and thrombosis were observed in the blood vessels where the stent was located.
[0119] The mass loss rate of the stent is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. The corrosion rate of the stent in the body is normal and it can still provide effective support at the 6-month time point.
[0120] Comparative Example 3
[0121] In this example, an iron-based stent with a size of 3.0 mm x 8 mm was used. A zinc layer with an average thickness of 1 μm was electroplated on the substrate surface as a metal barrier layer. A corrosion control layer with an average thickness of 4 μm was evenly sprayed onto the metal barrier layer using stent spraying equipment. The coating layer was made of poly(lactic acid) with a molecular weight of 800 kDa, and the solvent was chloroform. After the corrosion control layer dried, a drug-carrying layer with an average thickness of 4 μm was evenly sprayed onto the stent spraying equipment using poly(lactic acid) with a molecular weight of 400 kDa. The drug carrier was sirolimus, and the mass ratio of sirolimus to poly(lactic acid) in the drug-carrying layer was 1:2. The drug particles had an average particle size of 0.35 μm and were semi-crystalline. The solvent was ethyl acetate. After the drug-loaded layer is dried, a stent spraying device is used to evenly spray a drug release control layer with an average thickness of 15 μm. The coating is made of polyracemic lactic acid with a one-month molecular weight retention rate of 74% and a molecular weight of 200 kDa. The solvent is ethyl acetate.
[0122] The drug release rate of the stent in this comparative example in vivo is shown in FIG4 . As can be seen from FIG4 , the stent in this comparative example does not release enough drugs in the early stage and cannot play a therapeutic role in the early stage of implantation. At the 14-day time point, signs of thrombosis appeared in the blood vessel where the stent was located.
[0123] The stent's mass loss is shown in Figure 5, and its radial support strength is shown in Figure 6. The increased coating thickness and corresponding increase in the amount of polylactic acid resulted in accelerated in vivo corrosion of the stent, slowing initial drug release. After 60 days of implantation, the stent could no longer maintain its normal shape or provide effective support. Significant thrombosis was observed on the stent struts at 30 days, and severe restenosis was observed 90 days after implantation, with a lumen area loss exceeding 60%.
[0124] Comparative Example 4
[0125] In this embodiment, an iron-based bracket with a specification of 3.0 mm×8 mm is selected, and a zinc layer with an average thickness of 0.6 μm is plated on the surface of the substrate by electroplating as a metal isolation layer. On the surface of the metal isolation layer, a bracket spraying device is used to evenly spray a corrosion control layer with an average thickness of 2.5 μm. The coating layer uses polyracemic lactic acid with a molecular weight of 200 kDa and a solvent of chloroform. After the corrosion control layer is dried, a bracket spraying device is used to evenly spray a drug-loaded layer with an average thickness of 8 μm. The coating layer uses polyracemic lactic acid with a molecular weight of 200 kDa and a solvent of chloroform. The drug loaded is sirolimus. The mass ratio of sirolimus to polyracemic lactic acid in the drug-loaded layer is 1:8. The average particle size of the drug particles is 0.35 μm, and the drug particles are amorphous. After the drug-loaded layer is dried, a bracket spraying device is used to evenly spray a drug release control layer with an average thickness of 0.2 μm. The coating layer uses polyracemic lactic acid with a molecular weight of 100 kDa and a one-month molecular weight retention rate of 68%. The solvent is ethyl acetate.
[0126] The drug release rate of the stent in this comparative example is shown in Figure 4 , the mass loss of the stent is shown in Figure 5 , and the radial support strength of the stent is shown in Figure 6 . The corrosion rate of the stent in the body is normal and it can still provide effective support at 6 months. However, because the drug release control layer of the stent in this comparative example is too thin, the drug is released in bursts at an early stage, and most of the drug is released in the early stage of stent implantation, resulting in insufficient drug release in the middle and late stages. At 90 days, the blood vessels where the stent is located show signs of severe hyperplasia.
[0127] Comparative Example 5
[0128] In this embodiment, an iron-based stent with a size of 3.0 mm × 8 mm was used. A coating with an average thickness of 2.5 μm was evenly sprayed on the surface of the metal substrate using stent spraying equipment. The coating was made of polyracemic lactic acid with a molecular weight of 100 kDa and chloroform as the solvent. After the corrosion control layer dried, a drug-loaded layer with an average thickness of 5 μm was evenly sprayed using stent spraying equipment. The coating was made of polyracemic lactic acid with a molecular weight of 100 kDa and chloroform as the solvent. The drug loaded was sirolimus. The mass ratio of sirolimus to polyracemic lactic acid in the drug-loaded layer was 1:0.5. The average particle size of the drug particles was 0.25 μm, and the drug particles were in an amorphous state. After the drug-loaded layer dried, a drug release control layer with an average thickness of 0.2 μm was evenly sprayed using stent spraying equipment. The coating was made of polyracemic lactic acid with a molecular weight of 100 kDa and a one-month molecular weight retention rate of 68%. The solvent was ethyl acetate.
[0129] The in vivo drug release rate of the stent in this comparative example is shown in Figure 4, the mass loss of the stent is shown in Figure 5, and the radial support strength of the stent is shown in Figure 6. Due to the lack of a metal barrier layer, the stent matrix corroded rapidly, and the stent struts fractured early in implantation, resulting in accelerated drug release, with the majority of the drug released in the early stages of implantation. After 60 days of implantation, the stent could no longer maintain its normal shape and provide effective support. At 30 days, significant thrombosis was observed on the stent struts, and the tissue surrounding the stent struts showed abnormal color. After 90 days of implantation, the vessel experienced severe restenosis, with a lumen area loss exceeding 60%.
[0130] As can be seen from the above, compared with Example 4 and Comparative Example 1, due to the lack of a drug controlled release layer, Comparative Example 1 experienced a burst release of drug, releasing a large amount of drug in a short period of time, resulting in very little drug release for a considerable period of time in the middle and late stages, and low drug utilization.
[0131] Although Comparative Example 1 has the same drug-to-polyester mass ratio as Example 4, the lack of a controlled-release layer in Comparative Example 1 results in a large amount of drug released in a short period of time, resulting in minimal drug release for a considerable period in the middle and late stages, leading to low drug utilization. Comparative Example 2, on the other hand, differs in both drug particle morphology and solvent type, yet both lack a controlled-release layer, leading to rapid drug release in the body.
[0132] Compared with Example 4, although Comparative Example 3 has the same solvent and drug particle morphology, because the drug controlled-release layer is too thick, the drug release in the early and middle stages is insufficient, resulting in vascular hyperplasia and restenosis, and the drug treatment effect is also not achieved. In Comparative Example 3, because the polylactic acid coating is too thick and the polylactic acid content is increased, the stent corrosion rate in the body is accelerated. After 60 days of implantation, it can no longer maintain its normal shape and cannot provide effective support, which aggravates the symptoms of vascular thrombosis and restenosis.
[0133] Although both Comparative Examples 4 and 5 have drug controlled release layers, due to insufficient thickness of the drug controlled release layers, a large amount of drug is released in a short period of time after the surface polylactic acid is degraded, resulting in very little drug release for a considerable period of time in the middle and late stages, and low drug utilization.
[0134] However, in Comparative Example 5, due to the lack of a metal isolation layer and the lack of a corresponding polymer type and polymer molecular weight, the polymer is in direct contact with the stent substrate, causing the stent matrix to corrode too quickly and the stent rod to break in the early stage of implantation, resulting in accelerated drug release. After 60 days of implantation, the normal shape could no longer be maintained and effective support could not be provided.
[0135] In Examples 1-7, although the molecular weights, polymer materials, reagents, crystallinity, and drug particle sizes were different, after the drug controlled-release layer of appropriate thickness was prepared, no early burst of drug occurred, and the drug was released appropriately during the release cycle, which was relatively well matched to the degradation cycle of the stent substrate.
[0136] The present invention may have many other embodiments. Without departing from the spirit and essence of the present invention, those skilled in the art may make various corresponding changes and modifications based on the present invention, but these corresponding changes and modifications should all fall within the scope of protection of the claims attached to the present invention.
Claims
1. A coating for medical devices, characterized in that: The coating comprises a drug-loaded layer and a drug-controlled-release layer covering the drug-loaded layer, wherein both the drug-loaded layer and the drug-controlled-release layer contain a polymer, and the polymer in the drug-controlled-release layer has a molecular weight retention rate m and a weight average molecular weight Mw. 控释 and the thickness of the polymer X 控释 The following relationship is satisfied: in: A1 is the fitting constant, which is 823; A2 is the fitting constant, which is 79.9; k is the fitting constant, which is 1.5; b is the fitting constant, ranging from 0≤b≤2; The Mw 控释 is the weight average molecular weight of the polymer in the drug controlled release layer, in kilodaltons, X 控释 The unit is μm.
2. The coating for medical devices according to claim 1, wherein The weight average molecular weight Mw of the polymer in the drug controlled release layer 控释 The molecular weight retention rate m of the polymer is 50%-80%.
3. The coating for medical devices according to claim 1, wherein The mass ratio of the drug to the polymer in the drug-carrying layer is 1:(0.1-50).
4. The coating for medical devices according to claim 1, wherein The particle size r of the drug particles in the drug-carrying layer is less than or equal to 0.8 μm.
5. The coating for medical devices according to claim 1, wherein The sum of the thicknesses of the drug-loading layer and the drug-controlled-release layer is not less than 2.5 μm.
6. The coating for medical devices according to claim 1, wherein The molecular weight of the drug-carrying layer polymer is 30-1000 kDa.
7. The coating for medical devices according to claim 1, wherein The inner side of the drug-carrying layer also includes a corrosion control layer; the molecular weight of the polymer in the corrosion control layer is 50-1000 kDa.
8. The coating for medical devices according to claim 7, characterized in that The total thickness of the corrosion control layer, the drug-carrying layer and the drug-controlled-release layer is 3.5-45 μm.
9. The coating for medical devices according to claim 7, characterized in that The thickness ratio of the corrosion control layer, the drug-carrying layer and the drug-controlled-release layer is 1:(0.5-15):(0.2-13).
10. The coating for medical devices according to claim 7, wherein: The coating also includes a metal barrier layer located inside the corrosion control layer.
11. The coating for medical devices according to claim 10, characterized in that: The thickness of the metal isolation layer is ≥0.6 μm.
12. The coating for medical devices according to claim 1, wherein The polymer is at least one of a degradable polyester or a degradable polyanhydride; the polymer is selected from at least one of polyracemic lactic acid, poly-L-lactic acid, poly-D-lactic acid, poly(hydroxyethyl), polyurethane, polyamino acid, poly(lactic diglycolic acid) acid, poly-D,L-lactide, polypropylene glycol, polyglycolic acid, polylactic glycolic acid, polysalicylic anhydride, polytrimethylene carbonate, polycaprolactone, polycaprolactone, polyhydroxyalkanoate, polyacrylate, polysuccinate, poly(β-hydroxybutyrate) and polyethylene adipate, poly-1,3-bis(p-carboxyphenoxy)propane-sebacic acid, polyerucic acid dimer-sebacic acid and polyfumaric acid-sebacic acid.
13. The coating for medical devices according to claim 1, wherein The drug loaded in the drug-carrying layer is at least one of a drug for inhibiting angiogenesis, an anti-inflammatory drug, an antithrombotic drug and a sensitizing drug.
14. The coating for medical devices according to claim 1, wherein The drug loaded in the drug-carrying layer is at least one of paclitaxel, rapamycin, cilostazol, heparin, dexamethasone, tacrolimus, everolimus, calcium gluconate, chlorpheniramine or cortisone.
15. The coating for medical devices according to claim 1, wherein The medical device is a degradable medical device; the medical device is a degradable metal medical device or a degradable non-metal medical device.
16. The coating for medical devices according to claim 1, wherein The degradable medical device includes any one of a vascular stent, a heart valve, a non-vascular intraluminal stent, an occluder, an orthopedic implant, a dental implant, a respiratory implant, a gynecological implant, a men's implant, a suture or a bolt.
